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Meeting Purpose:
To discuss an operational research study on adolescent health and cervical cancer
prevention including HPV vaccines, to help support countries that have already made,
or will soon make a policy decision to introduce the HPV vaccine.
Background:
The Global Immunization Vision and Strategy (GIVS) of WHO and UNICEF calls for
reaching broader populations with vaccines by extending immunization programs to all
age groups. Adolescents typically have little contact with health services, particularly
for immunization programs. Since new HPV vaccines target adolescent girls, the
introduction of HPV vaccines may provide an opportunity for adolescents to engage
more with health services. This may create openings to offer more than vaccination, but
a package of adolescent health services that includes information, sexual and
reproductive health education, and adolescent health interventions. To better understand
the policy and programmatic issues related to delivering HPV vaccines as part of
comprehensive adolescent health services and for cervical cancer prevention, and as
stated in the WHO publication " Preparing for the introduction of HPV vaccines: policy
and programme guidance for countries" (http://www.who.int/reproductivehealth/publications/hpvvaccines/text.pdf) a study is proposed.
With the recent adoption of resolutions by the 48th Directing Council of the Pan
American Health Organization on adolescent health and on comprehensive cervical
cancer prevention and control, the region of the Americas has been given a political
mandate to improve adolescent health services and cervical cancer prevention. Thus, an
operational research study to assess the feasibility, acceptability, cost and means for
service delivery and monitoring adolescent health services, including cervical cancer
prevention and HPV vaccines would help support the implementation of these two
resolutions. And as there are several countries in the Americas initiating or considering
the introduction of the HPV vaccine, the timing for such a study is appropriate. A
meeting of potential study collaborators is proposed to discuss the proposal for an
operational research study and to refine and adapt the study objectives and protocol.
Meeting objectives:
1. To share information on country programs for adolescent health, sexual and
reproductive health, cervical cancer prevention and HPV vaccine introduction.
2. To present the proposed WHO adolescent health package, in relation to sexual
and reproductive health and cervical cancer prevention; and to discuss how the
package could be adapted and delivered, in relation to current adolescent health
services in countries.
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3. To discuss the proposed operational research study to assess the feasibility,
acceptability, cost and means for service delivery and monitoring of adolescent
health services, including cervical cancer prevention and HPV vaccines.
4. To define criteria for participating countries and study sites, collaborating
research centers and researchers.
5. To develop a work plan for the operational research study, for each participating
country.
Expected Outcomes of the Meeting:
1. A work plan for adaptation and development of the operational research study
that will commonly be applied in all participating countries.
2. A work plan to implement the operational research study, for each participating
country.
3. A suggested principal investigator for each country, and designated country
steering research committee.
Discussing the project to meeting participants:
The new HPV vaccine: an opportunity to improve adolescent’s health services
Representatives from several organizations (PAHO, WHO, UNFPA-Mexico, Center on
Equity and Reproductive Health, Ministry of Health Mexico –CERH- and the office on
Prevention and Control of HIV-AIDS-Mexico) discussed the importance of this meeting
that will allow participating countries the opportunity to share initiatives on the
introduction of the HPV vaccine and the ways in which introducing the vaccine can
improve health services for adolescents in four countries in the region of Latin America
and the Caribbean (Colombia, Peru, Panamá y México). The meeting would give
participating countries the opportunity to work as a group among different organizations
and across several programs (immunization, prevention of cervical cancer, reproductive
and adolescent health).
The seminal idea of using the HPV vaccine to offer health services to adolescents came
from the finding that adolescents tend not to access health services. In places where
there is access to specific packages for adolescent health, providers may not implement
them for several reasons (e.g. they do not know these packages are available, they do
not perceive adolescents as a group at risk, and they have concerns about the legal
implications of needing informed consent from parents of minors before they offer any
health service). The groups from participating countries in this meeting are either
considering the introduction of the HPV vaccine at the national level or have already
done so and aim to expand the package of services.
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The objective of this meeting was to discuss the feasibility of introducing the HPV
vaccine in combination with a comprehensive package of adolescent health services and
assess the strategy via a research protocol that follows an operations research (OR)
methodology.
The HPV vaccine as a key tool to prevent cervical cancer
The current project is based on the scientific evidence gathered to date on the
effectiveness of introducing the HPV vaccine to help prevent cervical cancer. This
evidence and the programmatic guidelines to introduce the vaccine are described in the
“green guide”, a document drafted by WHO, UNFPA and PAHO entitled “Preparing
for the introduction of HPV vaccines: policy and programme guidance for countries”
(see Sharepoint, guide HPV-WHO).
HVP infection is the leading cause of cervical cancer. In most women, the infection
disappears but chronic infection of some of the HPV genotypes can produce cellular
changes in the cervical uterine region. Industrialized countries have been successful in
reducing the death rates attributed to cervical cancer with integrated programs that
combine: 1) information and education to women regarding the disease and ways to
prevent it; 2) screening; 3) diagnosis and treatment; and 4) palliative care. Introducing
the HPV vaccine could strengthen these programs by preventing the infection by the
HPV virus. There are two vaccines currently available: Gardasil and Cervarix that offer
protection against four HPV strains and are administered in three doses. The vaccine is
more effective when it is administered prior to the initiation of sexual activity.
Introducing the HPV vaccine, unlike other vaccines, creates important barriers due to
factors such as its high cost and access to the target age group. First, introducing the
vaccine requires coordinating different programs and institutions including vaccination
programs, cervical control programs, overall health system delivery and the Ministry of
Education, among others. The decision to introduce a vaccine must be based on the
burden of disease, its cost-effectiveness, sustainability and, if the country in question
has the resources and infrastructure needed to introduce it. The groups from each
participating countries will have to define the feasibility of introducing the vaccine in
their context, the strategy they will need to supply the vaccine. Important considerations
include vaccine introduction (via health education campaigns or through schools,
defining the appropriate target population and, if it is feasible, carrying out a “catch-up”
For adolescents who have not previously been linked into the health system. Legal
aspects such as informed consent and whether the vaccine would be obligatory must be
considered together with other factors such as the developmental stage of adolescents.
Comprehensive package of adolescent health services
WHO suggests we capitalize on three points in time during which the HPV vaccine
is/could be administered in order to offer a comprehensive package of health services or
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a “plus” package for adolescents. WHO carried out an extensive literature review and
designed a “menu” of choices that could be included in such a package (see Table 1 and
Sharepoint documents “WHO ADO HPV Lit Review Report 2008 11 14 FINAL” and
“HPV Intervention Package for Adolescent Health”)
The types of components that could be included in the package are: screening (e.g.
anemia, vision), delivery of information (sexual and reproductive health, HPV,
nutrition), service provision (counseling, vouchers, referrals to other health services)
and delivery of supplies (e.g. Vitamin A, mosquito nets, vaccines such as hepatitis B
and tetanus). The contents of the package may vary according to the needs of each
country as well as the most appropriate target population to be included in a planned OR
study.
Table 1. Menu of options for a comprehensive package of health services for
adolescents
Category
Intervention

Definition

Menu of complementary
interventions

Screening

Test or screening for
diseases or disabilities

•
•
•

Anemia screening
Schistosomiasis screening
Visual screening (in appropriate
contexts)

Information
provision

Delivery of interventions
based on information,
included in information
sessions, skill building,
pamphlets.

•
•

Information on nutrition
Information on Sexual and
Reproductive Health
HPV information
Information on tobacco and
alcohol prevention

Referral to other health
services, counseling,
treatments

•

Supplies, direct provision
of basic products or
increased access to basic
products

•

Services

Delivery of
supplies

•
•

•
•

•
•
•

Vaccines

The vaccines identified to
complement the
administration of the HPV
vaccine (primary or

Referral to “vouchers” for health
services (including SRH).
Referral to visual screening
Referral to delivery of
iron/folate supplements
Antihelmintics (transmitted by
contact with floor)
Antihelmínticos
(schistosomiasis)
Mosquito nets for prevention of
malaria
Vitamin A

Tetanus/ Diphteria booster dose
Hepatitis B ( booster)
Costa Rica ( booster ADO P)
Meningococal (only to specific groups
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booster) for this age group

and high risk areas in LAC)
Typhoid (only for outbursts)
Rubeola (SR booster)

Introducing the HPV vaccine and the comprehensive package of adolescent health
services in the region of Latin America and the Caribbean: a strategic opportunity
The LAC region has the largest cohort of young adults aged 10-24 and the most
inequitable distribution of income in the world. Most of these young people come from
low income strata and have a high prevalence of unwanted pregnancies. Implementing
this project constitutes a strategic opportunity since the political climate seems ripe for
it. In 2008, El Salvador hosted a regional meeting that convened presidents and key
stakeholders who drafted a youth plan aimed at improving the sexual and reproductive
health of adolescents for the next ten years. The HPV vaccine could constitute an
important opportunity to address all forms of inequality in the region.
In May of the same year, 2008 a meeting was organized in Mexico to discuss the state
of the art and recent developments in the field of the HPV vaccine (“Towards the
prevention and comprehensive control of cervical cancer”– see Sharepoint, document
HPV_MEX Declaration).
A few months later in September 2008, the organizing committee from PAHO and
WHO drafted a resolution entitled “Strategy and regional action plan for the prevention
and control of cervical cancer” (see Sharepoint, document CD48 R10 Cancer
cervicouterino-Esp). During this meeting, the committee called the member states to
introduce the HPV vaccine if the price was feasible and financing became sustainable.
PAHO offered technical assistance to strengthen integrated cervical cancer programs
and support decision makers who showed an interest in introducing the vaccine.
Presentations on the current situations in participating countries with respect to
adolescent health, the HPV vaccine, and opportunities for introducing a
comprehensive adolescent health package
Each country presented their country profile, the way their health care system was
organized, current status of adolescent health and an update on the HPV vaccine. For
more detailed information you can access the power point presentations in Sharepoint.
Mexico – Dr. Patricia Uribe (National Center on Equity and RH-MOH)
Context and adolescent needs: The Federal MOH has several programmatic areas that
oversee adolescent health. The National Center on Equity and RH (NCERH) is in
charge of the cervical cancer program and currently does not have the technical
expertise or experience working with adolescent health. The most common health
problems among adolescents in Mexico include: early initiation of sexual activity (20%
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start between 15-19 years); pregnancy at an early age (18 years in rural areas); and a gap
between knowledge and practice. For example, n spite of having high levels of
knowledge of contraceptive methods, 90% report having had their first sexual
experience without protection. Other problems include the increasing incidence of
sexually transmitted infections and high rates of dating violence in this age group. The
MOH has designed youth friendly services to avoid the barriers associated with
traditional services such as lack of knowledge of bureaucratic procedures from the
patient’s perspective, lack of knowledge of legal aspects of service delivery to minors
from the provider’s perspective, office hours that are not convenient to adolescents,
among others. As is common in most countries, women are more frequent users of
health services than men and tend to seek care for issues regarding maternal health.
Cervical cancer context: In Mexico, cervical cancer is still the leading cause of cancerrelated death in the poorest areas of the south that border with Central America (breast
cancer is the leading cause of death at the national level). In these areas, cytology
coverage is low. The National Institute of Public Health of Mexico carried out a pilot
study on strategies aimed at decreasing the prevalence of cervical cancer. Based on their
initial findings and following their technical advice, in 2008, the NCERH selected the
125 communities (“municipios”) with the lowest level of human development indexes
in the country and began an HPV vaccine program for all adolescent girls between 9
and 12 years. Due to budgetary restrictions, they were unable to include a larger number
of communities. It has been shown that these communities have the highest risk of
acquiring cervical cancer. As part of the intervention, DNA testing for cervical cancer
was also offered to women. In 2009, the MOH plans to administer the HPV vaccine and
DNA testing to more communities throughout the country. The intervention will stress
the need to carry out the Papanicolau test as well as increase coverage of DNA testing at
the national level. Similarly, the MOH plans on strengthening the quality of diagnosis
and treatment that is currently offered free of charge to all women in Mexico. The HPV
vaccine is currently administered thru the school system and community centers via a
health education marketing campaign. While some challenges remain, the vaccine has
been very well accepted and key stakeholders have the political and social will to carry
out this project successfully.
The HPV vaccine: In 2008, the MOH purchased the HPV vaccine for $ 436.47 pesos
per dose (current exchange rate is 13.5 pesos per $1 USD). The national health security
system later bought it at a lower price of $ 327.00 pesos per dose and the Mexico City
MOH was able to buy it at $ 21.00 USD as greater competition among the
pharmaceutical companies that manufacture the vaccine arose. At the beginning, the
vaccine was administered in the following schedule of 0, 2 and 6 months. Researchers
are currently trying to define the feasibility of administering it at 0 and 2 months (for 9
yr olds) and at 60 months (for 15 yr olds). This schedule is based on one implemented
successfully in Quebec, Canada. The period of time between the second and third dose
will provide ample time to determine the need for administering the third dose.
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Panama – Dr. Yadira Carrera (Ministry of Health)
Context and adolescent needs: As in the rest of the LAC region, Panama has a high rate
of adolescent pregnancy (18%). The Ministry of Health and Social Development of
Panama has health programs targeted for adolescent and recently launched a teen
pregnancy prevention program in collaboration with UNFPA (2006-2008). The country
also has a comprehensive adolescent health program. Nevertheless, this program has
access barriers such as lack of space for teenagers seeking medical care and provider
training needs so that they can offer care to adolescents accompanied by their parents.
In addition, the country has to face the challenge of the opposition from the Catholic
Church towards the use and distribution of contraceptive methods.
Context of cervical cancer: HPV infection is the fifth leading cause of morbidity in
Panama. At the national level, cervical cancer is the second leading cause of death
followed by breast cancer. Most cases are concentrated in rural areas. The country has a
cervical cancer screening program which is especially difficult to implement in rural
areas due to the distrust associated with Pap tests among the population. The country
needs to reinforce existing training among providers, health education campaigns as
well as train laboratory personnel and develop adequate technical infrastructure to carry
out screening tests.
The HPV vaccine: In October 2008, Panama added the HPV vaccine to their
comprehensive immunization program. The vaccine is offered free of charge to 10 year
old girls (10 to 10.11 months) in three doses. The vaccine will be offered through the
public health system and in MOH clinics. They have developed the service provision
delivery system for the vaccine.
Peru – Dr. Lourdes Palomino (Ministry of Health) and Dr. Mario Martínez
(PAHO)
Context and adolescent needs: In Peru, one fifth of the population is of adolescent age,
living in cities, 60% are migrants from rural areas and 20% have low levels of
schooling. Rural areas have the highest rates of adolescent pregnancies. Contraceptive
coverage is low, STI transmission is high and the country has high rates of gender based
violence, including sexual violence. The MOH is currently undergoing health care
sector reform and moving toward access to universal health care. The current strategies
aimed at adolescents include sexual and reproductive health together with mental health
services that are offered throughout 700 youth friendly clinics where adolescent access
services using a “carnet.” As part of these youth friendly services, the MOH has also
included social and personal skill building that allow adolescents to act as community
leaders in a peer-based service delivery system.
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Context of cervical cancer and the HPV vaccine: Dr. Martínez stressed the benefits that
vaccines have in the epidemiology of diseases. Peru has a high rate of cervical cancer,
especially in rural areas with extreme poverty that are difficult to access such as the
jungle region. The HPV vaccine has not been introduced in Peru yet although the MOH
carried out a pilot study with an international NGO (PATH) in three sites (Piura,
Ayacucho and Ucayali) with the aim of assessing a future implementation strategy that
measures acceptability among the population and among providers and determines the
resources that will be needed and if the HPV vaccine constitutes a health priority in
Peru. Girls enrolled in school participated in the study once their parents had given
informed consent. The vaccine was administered in three doses at 0, 2 and 6 months.
Over 1,000 girls received the vaccine and large coverage was achieved. The cost per girl
for three doses was $90 USD; this price included total costs such as transporting the
vaccine, provider’s salaries, etc.).
Colombia - Sonia Bedoya (Government Province of Medellin) and Marion Piñeros
(National Cancer Institute)
Context and adolescent needs: In Colombia, 13.7 % of women between ages 15 and 19
report having their first sexual relationship before they reach 15 years; 80% of women
in that same age group currently do not use a contraceptive and only 38.2 % have ever
used a contraceptive method. These figures illustrate an important unmet need for
family planning methods in Colombia. The MOH is actively working to strengthen
adolescent health programs and facilitate access to services and methods.
Context of cervical cancer: Cervical cancer is the leading cause of death in Colombia. A
National Health Plan 2007-2010 was drafted and one of its goals is to reduce the
mortality associated to cervical cancer. Early screening and detection in the country is
acceptable (77% in the last 3 years) but they still have to work on coordinating
screening, detection and treatment. Colombia has considered carrying out a pilot study
focusing on the areas with the highest cervical cancer prevalence among the most
vulnerable groups. A prior study documented the most common HPV strains associated
with cervical cancer (16 and 18) were found to be most prevalent. The most aggressive
forms of HPV were found among women between ages 15 and 30 and a second peak
was found among women between ages 40 and 50 (often associated with sex outside of
marriage).
The HPV vaccine: The Colombian government supports the potential introduction of the
HPV vaccine. The factors they are taking into account include: burden of disease; costeffectiveness of the vaccine; and, logistical and financial sustainability. Because of the
current political conditions in the country, the government has a long list of unmet
health needs. However, each province has its own MOH and the discretionary power to
allocate resources according to need and to add health priorities to the National Health
Plan. The following ethical considerations will be taken into account when designing
the study methodology: will they select all girls or will they select particular
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communities and administer the vaccine to all girls? How will they address the social
reaction and doubts surrounding the vaccine’s efficacy? How will they address the
controversy of the booster dose? How will they design future screening programs? How
will they be able to increase parental consent for minors? How will they address
continuity of the vaccine for future cohorts? Researchers attending the meeting agreed
that an operations research methodology may help clarify some of these questions.
Colombia is planning on packaging the HPV vaccine as a strategy to prevent cervical
cancer and not as a vaccine to prevent STIs. The MOH is also interested in including the
vaccine as part of a comprehensive health package for adolescent health.
Lessons learned from two countries with experience introducing the HPV vaccine
Canada – Shainoor Ismail
Current program: The incidence of cervical cancer in Canada is decreasing. In 2008,
most provinces in the country have an HPV vaccine program and they are currently
administering Gardasil. They administer the vaccine to girls between ages 9 and 13
(before the beginning of sexual activity) in three doses (0, 2 and 6 months) as part of a
cervical cancer prevention program. It is offered in schools as a strategy that has proven
highly effective in Canada where acceptability is quite high. The vaccine was first
introduced with a social marketing campaign that used pamphlets, websites and other
dissemination materials. They determined that in order for the project to be costeffective, coverage had to be of at least 70%, a goal that was reached. Researchers have
noted the importance of carrying out a project that measures the impact of the
intervention, something they anticipate will yield positive results in the long term.
United Kingdom - Loretta Brabin
Current program: Since September 2008, the United Kingdom has had an HPV
immunization program. Cervarix is administered in three doses (0,1 and 6 months) to
girls between ages 12 and14 who are attending school. A catch-up program was
designed and the vaccine will be offered for three years to adolescents up to 18 years.
The vaccine was introduced together with a social marketing campaign stressing the
message that it prevents cervical cancer.
Prior challenges: Before the program was introduced, a study was carried out among
3,000 girls aged 12-13 to assess the feasibility and acceptability of the vaccine. Results
were quite favorable for both. Initial challenges included opposition from the Catholic
Church who opposed the vaccination scheme arguing they were “experimenting” with
girls. Another aspect that was debated was the finding that nurses in schools were not
always able to respond adequately to parents’ concerns especially when dealing with
those who opposed the vaccine. All these challenges were successfully addressed and
they ended up not having a negative effect on the overall acceptance of the vaccine.
Most of the questions put forth by parents had to do with side effects, risks associated
with the vaccine and if it would promote sexual promiscuity among the young girls.
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Another challenge included informed consent from the parents: nurses were not
comfortable administering the vaccine without parental consent and once parents found
out their consent was not needed; this made them more cautious about giving their
consent. Maintaining the adolescent’s confidentiality was also an important issue. Those
parents who initially opposed the vaccine and later gave their consent posed a
methodological dilemma since girls who joined the program later were not able to
follow the same treatment protocol. The coverage for the first dose was quite high at
83%. As part of the program, women aged 25 and older were reminded to seek
screening for cervical cancer. The experience from the United Kingdom illustrates that
despite initial concerns, the vaccine was highly acceptable and feasible to implement.
Coverage that does not reach traditional immunization programs is still high. However,
keeping girls aware and well informed is an ongoing challenge. In sum, the provision of
the HPV vaccine constitutes a good starting point to design a more structured program
around the sexual and reproductive health needs for adolescents.
Discussion:
The prior presentations generated a lively discussion about the challenges that lie ahead
for countries wanting to implement the HPV vaccine. The following issues could help
countries develop their operations research protocol: 1) schools are key sites to offer the
vaccine as part of a school health program (for those countries where such a program is
in place); 2) countries must reach a consensus on the way in which they plan to
implement the social marketing campaign and define the key messages regarding the
vaccine they wish to convey. For example, the United Kingdom promoted the program
as a way of preventing cervical cancer while other countries may chose to focus on a
campaign about sexual and reproductive health and STI prevention among adolescents.
Operations research (OR): proposed methodology
To inform the countries’ development of OR studies to test the HPV vaccine within a
comprehensive adolescent health package, Estela Rivero, researcher and professor from
El Colegio de México, provided a review of OR addressing basic concepts relevant to
design formative research and future interventions (The content of her presentation can
be found in Sharepoint, document “Introduction to OR.”)
The WHO’s proposal for carrying out OR was discussed by Dr. Garrett Mehl (see
Sharepoint, document “Design- Adolescent study -HPV”). For the OR project put forth
by WHO we need to take into account the three following questions:
•

What is the added value of administering the HPV vaccine as part of other
specific health interventions for adolescents including sexual and reproductive
health services?
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•

What are the repercussions of administering the HPV vaccine in an adolescent
“plus” package as part of the HPV immunization program (catch up, coverage,
etc.)?
What is the added value of including the HPV vaccine as part of the national
program of cervical cancer control?

•

The group’s hypotheses are that offering the “plus” package together with the HPV
vaccine will have a positive effect on knowledge and a reduction of sexual risk
behaviors among adolescents; that introducing the HPV vaccine together with the
“plus” package will not have a negative effect on the use, uptake or coverage of the
vaccine in the services offered to school aged children; and, that providing the HPV
vaccine will increase the use of screening services for cervical cancer from mothers of
the girls that were previously given the HPV vaccine.
The project will have three phases. In phase one, components that will be included in
the package will be defined, including the HPV vaccine. During phase 2, OR studies
that measure the feasibility, acceptability and determines aspects of monitoring,
evaluation and cost of the package will be conducted. Phase 3 will include a more
ambitious project that includes a case control methodology. The specific aspects of each
stage were described in the power point presentation.

Figura 1. Las tres etapas del proyecto para la introducción de la vacuna contra el VPH y el
paquete integrado.

|

Discussion:
After the methodological discussion regarding the OR projects, participants posed
questions regarding the feasibility of evaluating the impact of the intervention in terms
of a measurable behavioral change among the girls that received the HPV vaccine. They
concluded that based on some of the components of the package, it would be possible to
measure behavioral changes while noting that in the case of sexual and reproductive
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health the observable changes would be in terms of levels of knowledge. Participating
countries expressed some doubts regarding the best way of implementing the “plus”
package and the ethical issues that arise when budgetary restrictions do not allow them
to implement the package to all adolescents. All agreed that the HPV vaccine constitutes
a strategic opportunity to improve the coverage and use of health services among
adolescents and it is the task of each country to define their local context and
implementation mechanisms.
Evaluating the costs of introducing vaccines
Bárbara Jauregui discussed her experience implementing a PAHO initiative to
introduce new vaccines entitled ProVac, aimed at strengthening a country’s abilities to
make evidence based decisions on whether or not to introduce the HPV vaccine. Her
presentation entitled “Assessing costs in an operations research project” discussed the
topic of cost-effectiveness in introducing and sustaining new vaccines using the
following formula:
CEA= Program costs – costs avoided by preventing disease
_____________________________________________
Health benefits (DALYs)
CEA: Cost effectiveness analysis
DALYs: Disability Adjusted Life Years
For this project, the WHO developed a costing tool kit for health and development
services aimed at adolescents. This kit could be used to measure the costs associated
with introducing the HPV vaccine alone and in combination with the comprehensive
package of health services for adolescents. The kit can be adjusted depending on the
package of health services available in each country. The ProVac team is willing to
work together with the WHO to sharemethodologies, field work experiences and assess
the possibility of integrating tools in the future.
Preliminary ideas for an OR project in the four countries, challenges and next
steps
Using a series of questions as a guide, each country drafted a preliminary plan to
explore the potential components that could be included in the comprehensive health
package for adolescents in combination with the potential introduction of the HPV
vaccine and the initial methodological OR design (see presentations in Sharepoint).
Mexico
For Mexico, improving its cervical cancer control program thru the HPV vaccine for
adolescents is a priority together with an improving cervical cancer diagnosis and
treatment among women. The Mexico group concluded that it was indeed possible to
carry out a feasibility study to asses the acceptability of the “plus” package that is not
currently offered in the new HPV vaccine program. Researchers from Mexico were
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interested in participating with the other countries in this effort. The challenge would be
to adapt the package to communities by including the schools, the media and other key
players. Their main research questions included, among others: 1) Which interventions
from the “plus” package for adolescents and for women could be combined with the
HPV vaccine? 2) Are these interventions acceptable among the community and among
health professionals? 3) Will health care coverage among adolescents increase with the
increased coverage of the HPV vaccine? The group from Mexico would like to carry
out a situational analysis to assess the health needs in communities that could serve as a
basis for working with local health authorities. While Mexico has an adolescent health
package, its coverage is more widespread in urban areas. One of the aims will be to
assses the feasibility of adapting the adolescent health package to meet the needs of the
most vulnerable communities and those with the lowest human development indices in
the country. Components of the health package will include information on SRH, family
planning, gender equity, gender based violence, etc. The final components of the
package will be determined once the results of the situational analysis are available. The
country currenty has a vaccination card for adolescents aged 10 to19 years.
For the case of Mexico the intervention would include: adding the “plus” package of
health care services for adolescents to the HPV vaccine that is currently being
administered to girls in the poorest 125 communities in the country. More communities
with low human development indexes could be added if funding becomes available. The
information and services that could be included in the package could be: information on
SRH, nutrition, family violence, gender equity, STI and pregnancy prevention. Other
vaccines could be also administered together with condoms, folic acid and
contraceptives.
The package will be offered by health promoters (promotores de salud). The group
mentioned they could join efforts with the cervical cancer program at the MOH to carry
out the study. The key players involved in the study would be: The National Center for
the Control and Prevention of HIV/AIDS (Censida), The National Center for the Health
of Children and Adolescents, the National Institute of Public Health (INSP), health
caravans from the federal MOH, UNICEF, WHO, Population Council and others. This
group of experts will design and carry out the pilot phase of the study. In order to offer
the “plus” package they will need a multidisciplinary team and other partners such as
the National Institute of Epidemiological Reference and IMSS Oportunidades. They
will need to hire additional personnel to carry out surveys, do the training, draft data
collection instruments and analyze data. Next steps include convening an experts
meeting with key players, define more carefully the components of the “plus” package
and define the final study methodology.
Discussion:
Following Mexico’s presentation, unfortunately there was no time for group discussion.
Nevertheless, the country’s team will have to carefully address some of the topics raised
during the presentation such as the implications associated with the Mexican MOH
decision to use a different schedule than the one used and promoted by WHO. Until this
new schedule (two doses followed by a third booster dose at 60 months) is recognized
as an internationl standard, the Mexican government and its colleagues will not be able
to receive WHO funding for its OR study. The latter could be taken as an opportunity to
seek funding from new donors and seek new research partners which can lead to the
14

approval of this novel schedule and be considered the evidence based medicine needed
to provide the HPV vaccine.
Panama
Since October 2008, Panama has offered the HPV to girls starting at 10 years enrolled
in school. The OR proposed by the country team would use an experimental design by
offering the “plus” package in combination with the HPV vaccine. Given that the basic
adolescent health package offered in Panama already includes a series of screening tests
for vision, hearing, psycho social well being and accident prevention, the “plus”
element in the package would be to add the HPV vaccine together with 8 additional
sessions on health education that included topics such as cervical cancer, gender and
human rights. Panama has several models that could be adapted to the OR methodology.
The country team also considered adding recreational and sport activities for girls
receiving the vaccine. The study will compare the “plus” package in combination with
the HPV vaccine administered to 500 girls vs the “plus” package only administered to
500 girls conforming the control group. Mothers of girls receiving the vaccine will be
offered health education sessions that focus on prevention and cervical cancer
screening, effective communication strategies with their children, family violene,
women’s human rights, prevention of gender based violence and sexual exploitation.
The OR study will include a 24 week intervention: on day 0 they would administer the
HPV vaccine, the first educational session,and a baseline KAP survey. The intervention
will also include meetings with parents and violence surveillance. On day 30 they will
administer the second dose and the educational sessions with mothers and girls will be
given. On day 180 they will carry out the “post” KAP survey to assess change in these
indicators. The HPV vaccine with and without the “plus” health package for
adolescents will be offered in schools. The Gorgas Institute (a local research institute
with a representative attending the meeting) will offer technical assistance calculating
the sample size, random selection and implementing the study. The results obtained in
the KAP study will be used for purposes of monitoring and evaluation. Researchers will
measure attendance at educational sessions and positive change in reported family
violence. Keys partners will include: UNFPA, WHO, MOH Panama, Gorgas Institute,
among others. Country members expressed their interest in inviting local and
international NGOs that have experience working with adolescents such as the Red
Cross and the Lions Club. They will convene meetings with these groups to present the
OR study methodology and will work on a final version of the study protocol.
Discussion:
The country team discussed the selection criteria for the girls who will participate in the
study. The Gorgas Institute was chosen to calculate the sample. They mentioned they
would first have to know the coverage of the current health package for adolescents in
Panama targeted for adolescents between 10 to 19, although they believe it will be
somewhat difficult to measure real coverage. They concluded that administering the
HPV vaccine in schools may help strenghten the demand for other health services
among adolescents.
Colombia
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The group from Colombia thought it would be feasible to introduce the HPV vaccine in
the country given that the national government supports this health initiative. They also
mentioned that some important challenges lay ahead given that no formal agreement has
been reached. They propose to start implementing the OR project first. Among the
challenges they anticipate they included: political misgivings due to pressure that will
be exerted by the pharmaceutical industry; a MOH officials’ hesitation regarding
purchase of the vaccine; difficulty in accessing girls who live in impoverished or rural
areas that are often the ones with the highest rates of HPV; coverage of future cohorts;
and, costs of the vaccine. The Colombian governement is in the process of consolidating
the vaccination schedule for influenza virus and developing universal access to rotavirus
and pneumococus. The latter may delay or hinder the approval of the implementation of
the HPV vaccine. Participants also noted that while the above is worth considering,
provincial governments do have the autonomy to establish or create additional health
priorities provided they follow the guidelines dictated by the federal MOH and are
evidence based medicine interventions (e.g. burden of disese, cost-effectiveness and
logistical and financial sustainability).
The research questions posed by the group included: 1) How can we attain adequate
coverage of the HPV vaccine among the population most at risk? 2) How can we
achieve sustainability given the high cost of the vaccine? 3) How can we improve the
existing health services for adolescents maximizing the time the provider spends with
the patient? The group wanted to address two working hypothesis: the introduction of
the HPV vaccine in combination with the “plus” package will not have a negative effect
in the curent vaccine coverage; and, the provision of the “plus” package combined with
the HPV vaccine will improve the access and the service utilization among adolescents.
Currently, there is an adolescent health services program that includes visual and
anemia screening, growth and development. The “plus” package would add information
on SRH, the HPV virus and its association with cervical cancer, and prevention of
gender based violence. The convenience sample would consist of adolescent women
and the study will be carried out in the province of Medellín in two areas with low
levels of human development indices. The study will include an intervention arm
(“plus” package) and a control group (current adolescent health services and the HPV
vaccine using a social marketing campaign) in each study site. They will offer the two
options (both in private and in public clinics) thru their adolescent health service
networks. A careful selection of the population will be needed together with insuring
the availability of vaccines for future cohorts. The project’s success will depend on
political will and the possibility of securing funding to purchase the vaccine.
A KAP study will be carried out to measure the effect of the vaccine (including
knowledge of SRH and HPV and use of health services among adolescents and their
mothers). Other studies will include a cost-effectiveness analysis and an evaluation of
the quality of the services being offered. The following institutions will make up the
working group: health services in the sites selected to carry out the study; the Ministry
of Social Protection; the Colombian National Cancer Institute; and, the WHO and
PAHO country offices. They will ask the latter for technical assistance to help with the
negotiation with local key players (MOH) and provincial governments. Colombian
researchers are interested in sharing expertise and experiences with other countries in
the region that have introduced the vaccine and discuss their adolescent health
programs. Next steps will include involving the Ministry of Social Protection, design a
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work plan to discuss with the communities that will participate in the study, define
budgets and implement the project.
Discussion:
Participants raised the question about the need to include the community, local NGOs
and academic centers once a final methodology is defined. Colombian participants were
unaware if the federal government would purchase the vaccine although they thought it
would be up to the provincial governments do so. Medellin, is one example of a
province who would be willing to purchase it since they already carried out a costeffectiveness study.
Another issue that was raised was: if Colombia has a network of adolescent health
services, what would be the added value of implementing the “plus” package or the
HPV vaccine? A possibility mentioned was that of raising awareness of the existence of
such health services which would in turn increase the demand for services. Participants
noted that the network of adolescent health services does not have a wide coverage or a
comprehensive approach to prevention, detection and treatment. By introducing the
“plus” package and the HPV vaccine, they could improve the quality and coverage of
available services. The option of offering the “plus” package in combination with
another type of vaccine was mentioned, using Hepatitis B as an example. They did
acknowledge however, that by administering a different type of vaccine, they would
lose the focus of the project. Researchers mentioned the need to improve current
screening services for cervical cancer by implementing the “plus” package and the HPV
vaccine.
Peru
In Peru the HPV vaccine is only administered in private clinics even though the MOH
has a comprehensive health package for adolescents and a national immunization
program. The country team mentioned that it would be feasible to assess the
introduction of the HPV vaccine and they would be willing to work jointly with other
country participants. The challenges that lie ahead include: the country has low
coverage and access to current health services for adolescents; and, there seems to be
insufficient coordination between the national vaccination program and the life stages of
adolescents.
The adolescent health package currently available in Peru shares some similarities with
WHO’S “plus” package. They both have screening for hearing and vision, growth
charts, psychosocial health and information on SRH. For the study on OR the
adolescents who are currently receiving the available health package could serve as the
“control” group. Key players involved in the project would include: the MOH
(Immunization Program, SRH Program, Epidemiology Division, offices of
communication and provision of drugs, IRB and a group of external consultants.
Partners would include, WHO, PAHO, UNICEF, etc. Participants mentioned the need
to secure technical assistance and sufficient financial resources to purchase the vaccine.
Next steps would include convening a meeting with the MOH to discuss the future
introduction of the HPV vaccine that would be followed by a social marketing
campaign, a cost-effectiveness study, establishment of alliances and parterships and
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technical assistance to distribute the vaccine which would be offered thru the public
health sector at the national level. The OR project would focus on three areas where the
vaccine would be administered in schools and in health community centers. The
research question put forth by participants was: will the “plus” package improve the
current health services for adolescents available in Peru? The country team mentioned
they would draft a report with preliminary results and conclusions derived from the
Mexico City expert’s meeting, design a study methodology and meet with key players
at the MOH to define a future strategy. Once this is completed, they would present an
OR research protocol to their local IRB and would seek technical assistance from
PAHO. The girls who received the HPV vaccine in the year 2008 with the PATH pilot
test would conform the “control” group and the girls that will receive the “plus”
package would be the intervention group. They will also assess if the mothers of the
girls that received the vaccines had their Pap tests.
Discussion:
Participants from Peru questioned the ethical issue associated with forming a control
group since by law, all adolescents are eligible to receive health services. They
mentioned it was questionable not to include them in the intervention arm of the study.
A few alternatives were discussed, including: design a study where all girls receive the
package alone and later in time, receive the “plus” package and the HPV vaccine (once
the vaccine is available in the country). Other questions included if the “plus” package
had other benefits aside from increasing cervical cancer screening among mothers of
girls who receive the vaccine. Another possibility could be that the “plus” package
could also increase adherence to other types of vaccines or improve health, lifestyles,
and nutrition. The OR study variables should be clarified in order to reach consensus
with the MOH and to overcome the barriers and resistance the vaccine.
Conclusion and next steps
All country participants expressed their commitment and willingness to move forward
with the introduction of the HPV vaccine, the “plus” package, and assess the impact of
these interventions through an OR project in their respective countries. However, it is
clear that every country has very particular circumstances and is at different stages of
introducing the vaccine, which in turn raises other challenges and opportunities. For
example, Mexico and Panama already have a strategy in place and are offering the
vaccine but will need to consider carefully how best to proceed with the “plus” package.
All countries will have to think through the best way they could integrate the HPV
vaccine into their current health services for adolescents. Peru and Colombia on the
other hand are at the stage of starting discussions with health authorities about the need
to introduce the HPV vaccine in their health system as well as securing the essential
funding to purchase it. By the end of the meeting, each country had drafted a
preliminary OR plan and mapped out next steps. All teams needed to gather additional
input and consensus from key stakeholders in their respective countries before
elaborating study protocols.
Next steps:
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1. Each country will continue working and refining the implementation of the “plus”
package and post it on the meeting Sharepoint. They will share study instruments,
experiences and power point presentations; they will use “Elluminate” to facilitate
follow-up
2. WHO and PAHO will help countries to further develop the study methodology and
design of OR protocol
3. Garrett Mehl will draft a summary of lessons learned in the meeting
4. WHO and PAHO will draft a publication based on the meeting report, including
lessons learned and next steps that will be available in Sharepoint and will be open to
comments from country participants
5. WHO and PAHO have an international and regional task force that can offer
technical assistance and support in specific areas, such as the designing the costeffectiveness study
6. With the aim of serving as a case study, Sharepoint will open a space where countries
will be able to upload basic information on sexual and reproductive health indicators,
age of menarche, percentage of indigenous girls, prevalence of cervical cancer and HPV
vaccine, availability of the HPV vaccine, which will be useful for elaborating their
country protocols.
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